#Sweden #Stockholm #Nevisense #SciBase #Pia Renaudin

Leadership Transition at SciBase

SciBase Holding AB, a prominent name in AI-driven dermatology solutions, has officially announced a significant change in its senior management. On July 28, 2026, the company confirmed that its CEO Pia Renaudin will step down from her position. After nearly three impactful years leading the firm, Renaudin has decided to accept a new role elsewhere, with her tenure extending until December 31, 2026.

This leadership transition comes at a time when SciBase is solidifying its strategy aimed at enhancing its presence in the U.S. market, particularly focusing on Nevisense, its flagship product designed for skin cancer diagnostics. Despite Renaudin's departure, the company's core objectives and plans remain steadfast, guided by an experienced management team. This team is well-prepared to continue advancing the company’s growth agenda during the recruitment period for a new CEO.

Jesper Hoiland, Chairman of the Board, expressed his deep appreciation for Renaudin’s contributions, noting, "Pia has played a crucial role in shaping our strategy and organizational structure, which positions us well to exploit the full potential of Nevisense." Under her guidance, SciBase not only strengthened its footprint in the U.S. but also built a skilled team focused on expanding Nevisense’s application in cancer diagnostics.

Renaudin echoed this sentiment, stating, "I am proud of the extraordinary progression SciBase has made during my tenure. The foundation is now solid, and I believe it is the right moment for a new leader to take the helm. I am immensely grateful to Jesper, the Board, and the entire team for their dedication to improving lives through better cancer diagnostics."

In an immediate succession plan, the Board has started the search for Renaudin's successor. The decision to part ways is strategic, allowing for fresh leadership to navigate the company's next chapter without disrupting its established trajectory.

Established on a strong basis of over two decades of research from the Karolinska Institute in Stockholm, SciBase has positioned itself as a leader within the realm of medical technology. The firm's dedication to improving skin health through early detection using cutting-edge AI technology underscores its mission to reduce patient suffering and enhance care.

As SciBase continues to drive forward, there is great anticipation regarding future developments, particularly the ongoing collaboration with Castle Biosciences, which promises to expand the offerings associated with Nevisense. With the U.S. organizational structure already led by Leda Beaty, the future appears promising as the company sets its sights on advancing its contributions to dermatological science and patient care.

Looking ahead, the next steps for the Board and the incoming management team will be pivotal in maintaining the positive momentum built over the years. As recruitment for the new CEO unfolds, stakeholders remain optimistic about SciBase's trajectory in the healthcare industry.

In conclusion, while the transition marks the end of an era with Pia Renaudin at the helm, it also opens doors for new opportunities and strategic developments for SciBase as it continues to navigate the rapidly evolving landscape of dermatological diagnostics.